Cwm LLC Sells 75 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Cwm LLC trimmed its stake in Shockwave Medical, Inc. (NASDAQ:SWAV) by 26.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 212 shares of the company’s stock after selling 75 shares during the quarter. Cwm LLC’s holdings in Shockwave Medical were worth $40,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Covestor Ltd increased its holdings in Shockwave Medical by 484.9% during the third quarter. Covestor Ltd now owns 427 shares of the company’s stock worth $85,000 after buying an additional 354 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Shockwave Medical by 18,122.1% in the 4th quarter. International Assets Investment Management LLC now owns 141,586 shares of the company’s stock valued at $26,981,000 after purchasing an additional 140,809 shares during the last quarter. American Century Companies Inc. grew its holdings in Shockwave Medical by 109.0% during the third quarter. American Century Companies Inc. now owns 170,866 shares of the company’s stock worth $34,019,000 after purchasing an additional 89,094 shares during the period. AMI Asset Management Corp acquired a new position in Shockwave Medical during the fourth quarter worth approximately $4,092,000. Finally, HealthInvest Partners AB acquired a new stake in shares of Shockwave Medical in the fourth quarter valued at approximately $673,000. Institutional investors and hedge funds own 95.35% of the company’s stock.

Insider Transactions at Shockwave Medical

In related news, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $231.56, for a total value of $2,315,600.00. Following the transaction, the chief executive officer now directly owns 162,762 shares of the company’s stock, valued at $37,689,168.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Frederic H. Moll sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $257.39, for a total value of $15,443,400.00. Following the sale, the director now directly owns 287,521 shares of the company’s stock, valued at $74,005,030.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $231.56, for a total value of $2,315,600.00. Following the completion of the transaction, the chief executive officer now owns 162,762 shares in the company, valued at approximately $37,689,168.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 83,120 shares of company stock valued at $21,319,021. Company insiders own 3.40% of the company’s stock.

Shockwave Medical Price Performance

Shockwave Medical stock opened at $330.54 on Friday. The firm has a market cap of $12.40 billion, a PE ratio of 85.41, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The stock’s fifty day moving average price is $307.14 and its two-hundred day moving average price is $241.29. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings results on Monday, May 6th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.45. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The company had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $207.69 million. During the same quarter last year, the business earned $1.03 earnings per share. Shockwave Medical’s revenue was up 35.8% on a year-over-year basis. As a group, research analysts expect that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. SVB Leerink reissued a “market perform” rating and set a $335.00 target price (down from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th. Wolfe Research reaffirmed a “peer perform” rating on shares of Shockwave Medical in a report on Friday, April 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $335.00 price target (up from $270.00) on shares of Shockwave Medical in a report on Monday, April 8th. TheStreet upgraded Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Finally, Wells Fargo & Company lifted their price target on Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $309.11.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.